Singapore's Nuevocor raises $45 M to develop mechanobiology-centered therapy for cardiomyopathy
May 6, 2025 | Tuesday | News
Proceeds will support the Phase 1/2 clinical trial of lead candidate, NVC-001
image credit- shutterstock
Nuevocor, a Singapore-headquartered IND-stage biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, has announced the successful completion of $45 million Series B financing.
The round was co-led by Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio and Boehringer Ingelheim Venture Fund, alongside Highlight Capital and SEEDS Capital. Nuevocor is pleased to welcome Amanda Gett-Chaperot, PhD (Kurma Partners) and Elia Stupka, PhD (Angelini Ventures) to its Board of Directors.
The new investment will support a first-in-human, open-label, multicenter, ascending single-dose Phase 1/2 clinical trial of NVC-001 in patients with LMNA DCM, with clinical trial sites across the US and Europe. Additionally, the company will establish an office in Paris, France, to support clinical development and bring Singapore innovation to patients globally.
Lamin A/C (LMNA) mutations cause familial dilated cardiomyopathy (DCM). LMNA DCM is a genetic heart condition caused by mutations in the LMNA gene, leading to the weakening and enlargement of the heart muscle, ultimately resulting in a rapid progression toward end-stage heart failure.
LMNA DCM is estimated to affect more than 100,000 patients in the US and Europe. NVC-001 and other pipeline assets are derived from Nuevocor's proprietary PrOSIA mechanobiology platform, which pinpoints the functional root-cause of many cardiomyopathies.
